Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford’s vaccine manufacturing research team has today published a pre-print paper demonstrating the feasibility of a step change in the speed and volume of production of adenovirus-vectored vaccines against new virus variants or other future pandemics.

Vaccine manufacture

The researchers believe their work could enable Oxford’s ChAdOx vaccines to hit the “moonshot” objective set earlier this year by the Coalition for Epidemic Preparedness Innovations (CEPI), which aims to help compress vaccine development timelines to 100 days from pathogen identification to mass production, potentially including distribution of millions of doses from manufacturing sites around the world.

The same team recently published a detailed account of its invention of a new manufacturing method and ‘franchise’ approach to distribute production of the vaccine around the world. This has enabled over two billion doses of the Oxford/AstraZeneca vaccine to be produced – more than any other COVID-19 vaccine – with the majority both made and used in low- and middle-income countries.

The paper published today highlights the speed with which it would be possible to manufacture a new adenovirus-vectored vaccine at large scale.

Dr Dimitrios Doultsinos, John Black Research Fellow in Prostate Oncology at the Nuffield Department of Surgical Sciences, is co-author on the paper.

Read the full story on the Oxford University website

Similar stories

Prostate cancer AI diagnosis tool begins evaluation in Oxford

New artificial intelligence software that can help to spot prostate cancer is being trialled by researchers at Oxford University Hospitals (OUH) NHS Foundation Trust.

NDS SITU host first ever Surgical Trials Showcase

The first ever showcase of the Surgical Intervention Trials Unit, Nuffield Department of Surgical Sciences (NDS SITU) was hosted on Monday 23 January 2023 at the Richard Doll Building on Old Road Campus, Oxford, and also online.

Mr Gurdeep S. Mannu awarded Cancer Research UK Clinician Scientist Fellowship

Many congratulations to Mr Gurdeep S. Mannu who has been awarded a five-year Cancer Research UK Clinician Scientist Fellowship.

Blog posts

Marathon challenge for Prostate Cancer UK

Runners of all abilities started 2023 by challenging themselves to run 26.2 miles across January to fundraise for Prostate Cancer UK as part of the charity’s Run the Month: Marathon Edition.

Staff Census: We need you!

All Medical Sciences staff are invited to log into HR self-service and ensure their contact, diversity background and disability details are up to date. Between 6% and 27% of staff in the Division are missing their diversity data which makes it difficult to complete statutory reporting, understand or track our population changes and to plan actions around staff diversity and equality – make sure your data is complete today!

Oxford MedSci goes silver: 10 Years of Athena SWAN

The Medical Sciences Division is celebrating 10 years since its first Athena Swan bronze application, and the first year in which all 16 of its departments have achieved a silver award. The silver award recognises commitment to gender equality, understanding culture and context, and more. Read about our department’s hard work and innovation.